Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill amends the Public Health Service Act to change how biosimilar biological products are treated for interchangeability. It generally deems biosimilars interchangeable with their reference product after a 60-day transition unless limited by a preexisting "first interchangeable" exclusivity.
Liberals stress patient safety and notification safeguards.
Relative to its intended legislative type, this bill is a clearly targeted substantive statutory amendment that specifies how interchangeability determinations will operate going forward and integrates those changes into existing statutory provisions.
The bill amends the Public Health Service Act to change how biosimilar biological products are treated for interchangeability.
It generally deems biosimilars interchangeable with their reference product after a 60-day transition unless limited by a preexisting "first interchangeable" exclusivity.
The bill preserves any unexpired existing exclusivity periods, makes conforming statutory changes, and requires the FDA to update guidance within 18 months about data and review expectations.
Narrow regulatory reform with some bipartisan appeal but meaningful stakeholder opposition and procedural Senate barriers create moderate likelihood.
Relative to its intended legislative type, this bill is a clearly targeted substantive statutory amendment that specifies how interchangeability determinations will operate going forward and integrates those changes into existing statutory provisions. It provides concrete mechanisms (deemed interchangeability rules, transition timing, preservation of existing exclusivity, and guidance deadlines) that should be actionable within the current regulatory framework.
Liberals stress patient safety and notification safeguards.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals stress patient safety and notification safeguards.
Cautiously supportive of lower-cost access to biologics but concerned about patient safety and prescriber protections.
Worries the bill reduces evidence standards and could permit substitution without adequate safeguards or post-market monitoring.
Pragmatic view: the bill reduces regulatory complexity and could lower costs, but it raises tradeoffs about evidence, incentives, and legal risk.
Support likely conditional on FDA implementation details and preserved market incentives.
Generally supportive: the bill cuts regulatory red tape, encourages competition, and speeds biosimilar availability.
Sees the deeming approach as pro-market and consumer-friendly while keeping existing exclusivity intact.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow regulatory reform with some bipartisan appeal but meaningful stakeholder opposition and procedural Senate barriers create moderate likelihood.
The bill has not accumulated any surfaced votes yet.
Liberals stress patient safety and notification safeguards.
Narrow regulatory reform with some bipartisan appeal but meaningful stakeholder opposition and procedural Senate barriers create moderate l…
Relative to its intended legislative type, this bill is a clearly targeted substantive statutory amendment that specifies how interchangeability determinations will operate going forward and integrates those changes int…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.